Olmesartan Medoxomil in Atherosclerosis
Overview
This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.
Full Title of Study: “Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Double (Participant, Investigator)
Interventions
- Drug: Olmesartan medoxomil
- Drug: Atenolol
- Drug: Hydrochlorothiazide
- tablets
- Drug: olmesartan medoxomil
- tablets
- Drug: atenolol
- tablets
Arms, Groups and Cohorts
- Experimental: 1
- olmesartan medoxomil
- Active Comparator: 2
- atenolol
Clinical Trial Outcome Measures
Primary Measures
- Change of intima media thickness of the common carotid artery on the leading side of the neck.
Secondary Measures
- -Change in plaque volume in the common carotid artery or the carotid bulb.
- -Change of intima media thickness of the common carotid artery.
- -Changes of diastolic and systolic blood pressure.
- -Safety and tolerability
Participating in This Clinical Trial
Inclusion Criteria
- Mean sitting sBP and dBP prior to randomization of 140-180/90-105 mmHg – Increased cardiovascular risk, e.g.: a) documented or clinical signs of peripheral atherosclerotic disease stage IIa or lower; b) diabetes mellitus type 2; c) left ventricular hypertrophy on echo; d) current smoking; e) old myocardial infarction, stroke or TIA – Intima-media thickness of the common carotid artery greater than or equal to 0.8 and less than or equal to 1.6 mm (measured ultrasonographically) or the plaque volume of the carotid bulb greater than or equal to 4 μl and less than or equal to 500 μl Exclusion Criteria:
- Body mass index > 30 – Any type of known secondary hypertension – Electrocardiographic evidence of 2nd or 3rd degree atrioventricular block, atrial fibrillation, cardiac arrhythmia requiring therapy or bradycardia at rest (< 50/min) – Obstructive pulmonary disease – Claudicatio intermittens – History or clinical evidence of any significant gastrointestinal, respiratory, hematological, metabolic, immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient's participation in the trial – Hypersensitivity or contraindication to ARBs, Beta-Blockers, HCTZ or any cross allergy – Pre-treatment with ARBs or ACE inhibitors within 6 months prior to screening – Treatment with disallowed medication – Pregnant or breastfeeding females or females of childbearing potential without adequate contraception – History of alcohol and/or drug abuse
Gender Eligibility: All
Minimum Age: 35 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Sankyo Pharma Gmbh
- Provider of Information About this Clinical Study
- Petra Laeis, Daichi Sankyo Europe, GmbH
- Overall Official(s)
- Prof. Klaus O Stumpe, MD, Principal Investigator, Medizinische Poliklinik der Friedrich-Wilhelms-Universitat, Bonn, Germany
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.